Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027
Harmony Biosciences Holdings, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $31.81
-5.1% in 7d after detection
Post-detection moves
1h
—
1d
-1.4%
3d
-4.0%
7d
-5.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS